FOR IMMEDIATE RELEASE

EpiCypher® signs agreement with Thermo Fisher Scientific to deliver best-in-class ChIP-grade antibodies specific for histone PTMs

Research Triangle Park, NC and Carlsbad, CA – 24 April 2019 – EpiCypher®, a pioneer in the manufacture of functionalized recombinant nucleosomes, announced today the signing of an agreement with Thermo Fisher Scientific, the world leader in servicing science, to provide co-exclusive use of EpiCypher's SNAP-ChIP® technology. SNAP-ChIP® (Sample Normalization and Antibody Profiling for Chromatin Immunoprecipitation) is a proprietary spike-in control developed by EpiCypher that can be added to Chromatin immunoprecipitation (ChIP) assays for quantitative sample normalization and to monitor the specificity of antibodies. SNAP-ChIP incorporates DNA-barcoded recombinant modified nucleosomes to make ChIP truly quantitative, and is currently the only tool available for accurately identifying ChIP-grade histone PTM-specific antibodies.

"A major goal of this partnership is to fix the antibody specificity problem that has long plagued ChIP, and Thermo Fisher is the ideal partner to leverage SNAP-ChIP technology for the development of highly specific ChIP-validated antibodies," said EpiCypher President Jim Bone.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher® is a biotechnology company developing innovative and transformative technologies to researchers and drug developers worldwide. EpiCypher pioneered the manufacture of modified recombinant nucleosome, and uses this expertise to create products and assay platforms incorporating modified nucleosomes (dNucs). These include the SNAP-ChIP® product family for quantitative ChIP applications and the EpiDyne® product family for nucleosome remodeling assays. EpiCypher sells the best fit-for-purpose SNAP-ChIP-validated antibodies, and offers a broad range of custom nucleosome substrate manufacturing and assay development services.

Media Contact:
James Bone, Ph.D., President
919-558-1309 (direct)
jbone@epicypher.com